The company has not filed an annual or quarterly report since its Q1 FY2022 10-Q, filed May 12, 2022. Its latest SEC filing is a 15-12B from Jun 10, 2022.
10-Q for Q1 FY2022, filed May 12, 2022
The sections below describe the company as of the FY2021 annual report.
Develops vidutolimod, an investigational cancer therapy for patients with melanoma and other solid tumors, including for use with other immunotherapy drugs.
10-K for FY2021, filed Mar 30, 2022
10-Q for Q1 FY2022, filed May 12, 2022
−$15.9MView ↗
8-K, filed May 31, 2022
As described in the Introductory Note above, on May 31, 2022, Purchaser irrevocably accepted for payment all shares of Common Stock validly…View ↗
8-K, filed Apr 19, 2022
As previously announced, on April 18, 2022, Checkmate Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an…View ↗
Competes with Amgen, AstraZeneca, BMS, Genentech, GlaxoSmithKline, Merck &, Novartis, Pfizer, Regeneron, Roche Holding, Sanofi, TriSalus Life Sciences, Idera Pharmaceuticals, Bolt Therapeutics, and Silverback
10-K for FY2021, filed Mar 30, 2022The biotechnology and pharmaceutical industries, and the immuno-oncology subsector, are characterized by the rapid evolution of…View ↗
Loading...
